Global Telmisartan Market to Grow at a CAGR of 5.6% during 2024-2032, Aided by the Rising Use of the Drug in the Treatment for COVID-19 Infected Patients

The recent success of angiotensin receptor blocker (ARB) drugs such as telmisartan can be attributed to the tentative utilisation of the drug in the treatment of COVID-19 infected patients. The clinical trials on people aged 18+ showed significant results in the treatment of COVID-19 with a lower median time to discharge, from 15 days to 9 days, reduction in deaths, and a substantial reduction in the requirement of ventilation, along with no side effects. The study suggested that the drug is safe and could reduce morbidity and mortality in critically infected patients. In addition to this, telmisartan is used for treating chronic diseases like hypertension, thereby lowering the risk of stroke and cardiac arrests, which is continually delivering a positive influence on the industry growth.

The presence of online healthcare platforms, including 1mg, Netmeds, and PharmEasy, are creating growth opportunities for the wide reach of telmisartan drugs. Telmisartan is popularly used to treat chronic diseases like hypertension and other cardiovascular diseases. In the presence of these online channels, companies like Nippon Boehringer Ingelheim, and Pfizer, Inc (NYSE: PFE). among others, are able to make their products available worldwide. Thus, the existence of online delivery channels is boosting the sales of telmisartan and hence augmenting the industry growth.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Strength, Condition, Distribution Channel, and Region:

• Based on strength, the market can be segmented into 20mg, 40mg, and 80mg.

• The market, on the basis of condition, can be divided into hypertension, stroke, and cardiac arrest, among others.

• On the basis of distribution channels, the market segmentations include hospital pharmacies, and retail pharmacies and drug stores, and online. 

• The major regional markets for telmisartan are North America, Latin America, Europe, the Asia Pacific, and the Middle East and Africa. 

Key Findings of the Report:

• The telmisartan industry is primarily being driven by the prevalence and risk of cardiovascular and other chronic diseases like hypertension.

• The development of generic versions of telmisartan to provide cost-effective treatment for hypertension and cardiac diseases is expected to propel the industry growth.

• Significant contributions to study and explore the potential benefits of telmisartan in the treatment of kidney diseases are expected to augment market growth in the coming years. 

• Clinical trials for the tentative treatment of COVID-19 infected patients and the positive results of the drug are providing impetus to market growth. 

Key Offerings of the Report:

• The EMR report gives an overview of the telmisartan industry for the periods (2018-2023) and (2024-2032).

• The report also offers historical (2018-2023) and forecast (2024-2032) markets for strengths, conditions, distribution channels, and regions of telmisartan.

• The report analyses market dynamics, covering the key demand and price indicators in the market along with an assessment of the SWOT and Porter’s Five Forces Model.

The major players in the global telmisartan market are Novartis AG, Astellas Pharma Inc., Nippon Boehringer Ingelheim, Abbott, Hema Pharmaceuticals Pvt. Ltd., and Pfizer Inc, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790